1. Home
  2. EXFY vs SERA Comparison

EXFY vs SERA Comparison

Compare EXFY & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$0.94

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$2.28

Market Cap

107.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
SERA
Founded
2008
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Precision Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
107.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EXFY
SERA
Price
$0.94
$2.28
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.50
N/A
AVG Volume (30 Days)
557.3K
23.6K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.66
EPS
N/A
N/A
Revenue
$142,101,000.00
$77,000.00
Revenue This Year
$4.44
$25.84
Revenue Next Year
$0.56
$715.79
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$1.17
$1.37
52 Week High
$3.87
$4.35

Technical Indicators

Market Signals
Indicator
EXFY
SERA
Relative Strength Index (RSI) 25.73 31.88
Support Level N/A $2.26
Resistance Level $1.54 $3.45
Average True Range (ATR) 0.10 0.20
MACD -0.02 -0.01
Stochastic Oscillator 10.23 9.43

Price Performance

Historical Comparison
EXFY
SERA

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: